SARS-CoV-2 neutralizing antibody development strategies.
Bertan Koray BalcıoğluMelis Denİzcİ ÖncÜHasan Ümit ÖztÜrkFatıma YÜcelFiliz KayaMüge SerhatliHivda Ulbeği PolatŞaban TekİnAylin Özdemir BahadırPublished in: Turkish journal of biology = Turk biyoloji dergisi (2020)
In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.
Keyphrases
- sars cov
- angiotensin converting enzyme
- respiratory syndrome coronavirus
- endothelial cells
- angiotensin ii
- public health
- coronavirus disease
- dengue virus
- end stage renal disease
- healthcare
- induced pluripotent stem cells
- induced apoptosis
- chronic kidney disease
- newly diagnosed
- mental health
- south africa
- single cell
- prognostic factors
- high throughput
- pluripotent stem cells
- signaling pathway
- binding protein
- cell therapy
- health information
- cell cycle arrest
- cell proliferation
- oxidative stress
- small molecule
- climate change
- cell death
- patient reported
- social media
- health promotion